The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...

The company is currently awaiting topline data from the Phase 3 VERITAC-2 trial, which is expected to be released in the first quarter of 2025. This trial is crucial for Arvinas, as it will ...

The company is currently awaiting topline data from the Phase 3 VERITAC-2 trial, which is expected to be released in the first quarter of 2025. This trial is crucial for Arvinas, as it will provide ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Olema Oncology (OLMA) to $25 from $30 but keeps an Outperform rating on ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival ...

Topline results from the VERITAC-2 study showed that Arvinas-partnered vepdegestrant was able to extend progression-free survival (PFS) compared to the older degrader fulvestrant in a subset of HR ...

Those readouts include the VERITAC-2 trial of protein degrader vepdegestrant in second-line oestrogen receptor-positive metastatic breast cancer – the first key data from a drug Pfizer sees as ...